Our top pick for
Building a portfolio
LogicBio Therapeutics, Inc is a biotechnology business based in the US. LogicBio Therapeutics shares (LOGC) are listed on the NASDAQ and all prices are listed in US Dollars. LogicBio Therapeutics employs 39 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$5.00 - $10.00|
|50-day moving average||$7.61|
|200-day moving average||$7.42|
|Wall St. target price||$20.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.55|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$3.5 million|
|Gross profit TTM||$3.5 million|
|Return on assets TTM||-28.9%|
|Return on equity TTM||-62.91%|
|Market capitalisation||$200.2 million|
TTM: trailing 12 months
There are currently 832,912 LogicBio Therapeutics shares held short by investors – that's known as LogicBio Therapeutics's "short interest". This figure is 1% up from 824,401 last month.
There are a few different ways that this level of interest in shorting LogicBio Therapeutics shares can be evaluated.
LogicBio Therapeutics's "short interest ratio" (SIR) is the quantity of LogicBio Therapeutics shares currently shorted divided by the average quantity of LogicBio Therapeutics shares traded daily (recently around 134340.64516129). LogicBio Therapeutics's SIR currently stands at 6.2. In other words for every 100,000 LogicBio Therapeutics shares traded daily on the market, roughly 6200 shares are currently held short.
However LogicBio Therapeutics's short interest can also be evaluated against the total number of LogicBio Therapeutics shares, or, against the total number of tradable LogicBio Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case LogicBio Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 LogicBio Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0391% of the tradable shares (for every 100,000 tradable LogicBio Therapeutics shares, roughly 39 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against LogicBio Therapeutics.
Find out more about how you can short LogicBio Therapeutics stock.
We're not expecting LogicBio Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, LogicBio Therapeutics's shares have ranged in value from as little as $5 up to $10. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while LogicBio Therapeutics's is 1.2587. This would suggest that LogicBio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
LogicBio Therapeutics, Inc. , a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. .
Everything we know about the Talaris Therapeutics IPO, plus information on how to buy in.
Everything we know about the Sagimet Biosciences IPO, plus information on how to buy in.
Everything we know about the Zenvia IPO, plus information on how to buy in.
Everything we know about the Grove IPO, plus information on how to buy in.
Everything we know about the Pasithea Therapeutics IPO, plus information on how to buy in.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.